{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:00:46Z","timestamp":1787061646058,"version":"build-2736575974"},"reference-count":50,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":68,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["20131206"],"award-info":[{"award-number":["20131206"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R35AG71476"],"award-info":[{"award-number":["R35AG71476"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R25 AG083721\u201001"],"award-info":[{"award-number":["R25 AG083721\u201001"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM109025"],"award-info":[{"award-number":["P20GM109025"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["A&amp;amp;D Transl Res &amp;amp; Clin Interv"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>The minimum clinically important difference (MCID) is a measure of the minimal clinically relevant change. The MCID represents the smallest difference in score on the measure or domain of interest which patients or clinicians perceive as beneficial or as meaningful decline. The MCID is not an alternative clinical trial outcome; it does not apply to group measures and is used as a means of determining whether an individual patient has reached a threshold of change. MCIDs have been derived for symptomatic treatments and for disease targeted therapies. MCIDs have been derived for nearly all clinical trial instruments used in AD therapeutic research. Application of the MCID to patients on disease\u2010targeted therapies requires awareness of the expected increasing treatment\u2010no treatment difference exhibited by these agents. The MCID complements other strategies for assessing the meaningfulness of interventions including effect size, number needed to treat, responder analyses, time saved, quality of life, and quality\u2010adjusted life years. MCID is not a required measure for regulatory approval of a therapeutic since it is applicable to individual patients and not to group outcomes or mean differences used to determine treatment benefit in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>MCID is a key measure of within\u2010person change in cognition, function, or behavior when it is applied to metrics of Alzheimer's disease progression.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In Alzheimer's disease, MCID or minimum within person change (MWPC) can function as useful means of determining if a patient has progressed to thresholds of detectable change.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In Alzheimer's disease, MCID\/MWPC can be used to determine the number or percent of individuals who have progressed to detectable levels of within\u2010person change, with differences anticipated in active treatment and placebo groups.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>MCID\/MWPC are not measures that are appropriately applied to group outcomes of clinical trials.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/trc2.70059","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T11:22:08Z","timestamp":1741692128000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Perspective: Minimal clinically important difference (MCID) and Alzheimer's disease clinical trials"],"prefix":"10.1002","volume":"11","author":[{"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[{"name":"Department of Brain Health Kirk Kerkorian School of Medicine Chambers\u2010Grundy Center for Transformative Neuroscience University of Nevada Las Vegas (UNLV)  Henderson Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"ADUHELM\u00ae (aducanumab\u2010avwa) injection, for intravenous use","author":"Prescribing Information","year":"2022"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.5867\/medwave.2021.03.8149"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-200050660"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.4103\/aian.aian_207_23"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01344-w"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.06.005"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13770"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2607"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00197-8"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14050"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint14030051"},{"key":"e_1_2_6_14_1","volume-title":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)","author":"Food and Drug Administration","year":"2022"},{"key":"e_1_2_6_15_1","article-title":"Appropriate use of meaningful within\u2010patient change (MWPC) thresholds in Alzheimer's disease","author":"Lansdall CJ","year":"2024","journal-title":"Alzheimers Dement"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-024-03798-7"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/15412550902918402"},{"key":"e_1_2_6_18_1","article-title":"Donepezil for dementia due to Alzheimer's disease","author":"Birks J","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_6_19_1","first-page":"109","article-title":"Defining disease modifying therapy for Alzheimer's disease","volume":"4","author":"Cummings J","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.50"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-0721-9"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01124-2"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00350-y"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14134"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12411"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12959"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.11.1356"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.9.1323"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00005"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000346277"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2308"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/geronj\/44.3.M77"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2412-a"},{"key":"e_1_2_6_38_1","first-page":"227","article-title":"A combined measure of cognition and function for clinical trials: the Integrated Alzheimer's Disease Rating Scale (iADRS)","volume":"2","author":"Wessels AM","year":"2015","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00004"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-312383"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.3810"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-200310000-00002"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00723-1"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1379062"},{"key":"e_1_2_6_45_1","volume-title":"Guidelines for the clinical evaluation of antidementia drugs","author":"Leber P","year":"1990"},{"key":"e_1_2_6_46_1","volume-title":"Early Alzheimer's Disease: Developing Drugs for Treatment.Guidance for Industry","author":"Food and Drug Administration","year":"2024"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-00984-y"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-331941"},{"key":"e_1_2_6_49_1","first-page":"557","article-title":"Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta\u2010analysis","volume":"169","author":"Lanctot KL","year":"2003","journal-title":"CMAJ"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2766"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00757-8"}],"container-title":["Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.70059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:17:38Z","timestamp":1761491858000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/trc2.70059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/trc2.70059"],"URL":"https:\/\/doi.org\/10.1002\/trc2.70059","archive":["Portico"],"relation":{},"ISSN":["2352-8737","2352-8737"],"issn-type":[{"value":"2352-8737","type":"print"},{"value":"2352-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70059"}}